z-logo
open-access-imgOpen Access
Insights into Gastric Cancer
Author(s) -
Arun Kumar Vadikari,
Vishakante Gowda D,
Mahendran Bhaskaran,
Vikas Jain
Publication year - 2020
Publication title -
international journal of research in pharmaceutical sciences
Language(s) - English
Resource type - Journals
ISSN - 0975-7538
DOI - 10.26452/ijrps.v11i2.2164
Subject(s) - cancer , medicine , monoclonal antibody , cancer treatment , disease , metastasis , targeted therapy , immunology , antibody , pathology
Gastric Cancer (GC) is one of the serious diseases prevailing globally. GC has immense global life-threatening health issues by taking 4th place among all the widespread cancers and 2nd foremost reason for fatality around the globe. Numerous patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. In the present review, we have put forward all the possible advanced treatments for GC, which includes the application of Nanotechnology, Monoclonal antibodies, and Robotic surgery. Nanoparticle offers a potentially improved treatment of multidrug-resistant cancers. GC is uniquely positioned as an area of research for targeted and nanoparticle therapies. This review briefs about design and considerations to develop targeted nanoparticle-based approaches for overcoming physiological hurdles in GC treatment. Based on current knowledge, molecular and cellular mechanisms, a number of novel biologic approaches such as monoclonal antibodies have been recently introduced for cancer treatment that mainly affects the immune system or target signaling pathways playing a role in cancer and metastasis development. Surgical robotic systems have been presented into the area of GC therapy as an enhanced technology that has overwhelmed the technical limits of laparoscopy. A note is added to relevant studies dealing with treatment concepts and gives an overview of the latest trends and developments in the treatment of GC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here